Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1НИИПЗ СО РАМН, Томск, 2ГОУ ВПО НГМУ Росздрава, Новосибирск
Список исп. литературыСкрыть список 1. Аведисова А.С. Антидепрессанты: назад, в будущее. Психиат. и психофармакотер. 2006; 8 (4). 2. Мосолов С.Н. Биполярное аффективное расстройство: диагностика и терапия. Под ред. С.Н.Мосолова. М.: МЕДпресс-информ, 2008. 3. Angst J. The bipolar spectrum. Br J Psychiat 2007; 190: 280–1. 4. Bowles TM, Levin GM. Aripiprazole: A New Atypical Antipsychotic. Drug Ann Pharmacother 2003; 37: 687–94. 5. Collier DA, Stober G, Li T et al. A novel functional polymorphism within the promoter of the serotonin transporter gene: Possible role in susceptibility to affective disorders. Mol Psychiat 1998; 1: 453–60. 6. Deutschman DA, Deutschman DH, Jones J. Levetiracetam: Efficacy, Tolerability, Safety in Bipolar Disorder. Poster 373 presented at: 157-th annual meeting of the American Psychiatric Association. NY, 2004. 7. Goldberg JF, Hoop J. Rapid-Cycling Bipolar Disorder: Treatment Options for Rapid Cycling. Medscape Psychiatry & Mental Health, 2004; 9 (2). 8. Greist JH. Current use of carbamazepine and other anticonvulsants as lithium alternatives in bipolar disorders. Inter Clin Psychopharmacol 1990; 5 (1; Suppl. 1): 15–26. 9. Hanoun N, Mocaer E, Boyer PA et al. Differential effects of the novel antidepressant Valdoxan (S 20098) versus fluoxetine on 5-HT1A receptors in the rat brain. Neuropharmacology 2004; 47: 515–26. 10. Heils A, Teufel A, Petri S et al. Allelic variation of human serotonin transporter gene expression. J Neurochemistry 1996; 66: 2621–4. 11. Keck PE Jr, Perlis RH, Otto MW et al. Expert consensus guideline series: treatment of bipolar disorder. Postgrad Med Spec Rep, 2004. 12. Kennedy SH, Emsley R. Placebo-controlled trial of Valdoxan in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006; 16: 93–100. 13. Kupka R. Rapid cycling. Discrimination factors in rapid and non rapid cycling bipolar disorder. Thesis. University of Utrecht Press, 2003. 14. Loo H, Hale A, D\'Haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT2C antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol 2002; 17: 239–47. 15. Monteleone P, Maj M. Circadian rhythm disturbances in depression: implications for treatment and quality of remission. Medicographia 2009; 31 (2): 132–9. 16. Montgomery SA, Kennedy SH, Burrows GD et al. Absence of discontinuation symptoms with Valdoxan and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271–80. 17. Munoz C. Better quality remission in depression: Valdoxan, the first melatonergic antidepressant. Medicographia 2009; 31 (2): 175–81. 18. Nakamura M, Ueno S, Sano A et al. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Molecular Psychiatry 2000; 5: 32–8. 19. Papp M, Litwa E, Gruca P et al. Anxiolytic-like activity of Valdoxan and melatonin in three animal models of anxiety. Behav Pharmacol 2006; 17: 9–18. 20. Pollock BG, Ferrel RE, Mulsant BH et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587–90. 21. Post RM, Leverich GS, Nolen WA et al. A re-evaluation of the role of antidepressants in the treatment of bipolar depression: data from the Stanley Foundation Bipolar Network. Bipolar Disord 2004; 5: 396–406. 22. Ramamorrthy S, Bauman AL, Moore KR et al. Antidepressants and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proceedings of the National Academy of Sciences 1993; 90: 2542–6. 23. Salvatore P, Ghidini S, Zita G et al. Circadian activity rhythm abnormalities in ill and recovered bipolar I disorder patients. Disord 2008; 10: 256–65. 24. Smeraldi E, Zanardi R, Benedetti F et al. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiat 1998; 3: 508–11. 25. WHO – World Health Report: Mental Health: New understanding. New Hope. Geneva, World Health Organization, 2001. 26. Whyte EM, Pollock BG, Wagner WR et al. Influence of serotonin-transporter-linked promoter region polymorphism on platelet activation in geriatric depression. Am J Psychiat 2001; 158: 2074–6. 27. Zanardi R, Benedetti F, Dibella D et al. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Clin Psychopharm 2000; 20: 105–7.